CN102639553A - 纯化聚乙二醇化蛋白质的方法 - Google Patents

纯化聚乙二醇化蛋白质的方法 Download PDF

Info

Publication number
CN102639553A
CN102639553A CN2010800532840A CN201080053284A CN102639553A CN 102639553 A CN102639553 A CN 102639553A CN 2010800532840 A CN2010800532840 A CN 2010800532840A CN 201080053284 A CN201080053284 A CN 201080053284A CN 102639553 A CN102639553 A CN 102639553A
Authority
CN
China
Prior art keywords
factor
set forth
protein
purified
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800532840A
Other languages
English (en)
Chinese (zh)
Inventor
M.K.D.韦恩达尔
L.塞耶斯加尔德
A.博格斯内斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Priority to CN201710713355.9A priority Critical patent/CN107383158A/zh
Publication of CN102639553A publication Critical patent/CN102639553A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2010800532840A 2009-11-24 2010-11-24 纯化聚乙二醇化蛋白质的方法 Pending CN102639553A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710713355.9A CN107383158A (zh) 2009-11-24 2010-11-24 纯化聚乙二醇化蛋白质的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09176881.2 2009-11-24
EP09176881 2009-11-24
US26448609P 2009-11-25 2009-11-25
US61/264486 2009-11-25
PCT/EP2010/068112 WO2011064247A1 (en) 2009-11-24 2010-11-24 Method of purifying pegylated proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710713355.9A Division CN107383158A (zh) 2009-11-24 2010-11-24 纯化聚乙二醇化蛋白质的方法

Publications (1)

Publication Number Publication Date
CN102639553A true CN102639553A (zh) 2012-08-15

Family

ID=41401820

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710713355.9A Pending CN107383158A (zh) 2009-11-24 2010-11-24 纯化聚乙二醇化蛋白质的方法
CN2010800532840A Pending CN102639553A (zh) 2009-11-24 2010-11-24 纯化聚乙二醇化蛋白质的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710713355.9A Pending CN107383158A (zh) 2009-11-24 2010-11-24 纯化聚乙二醇化蛋白质的方法

Country Status (5)

Country Link
US (1) US8697844B2 (https=)
EP (1) EP2504349B1 (https=)
JP (1) JP5827955B2 (https=)
CN (2) CN107383158A (https=)
WO (1) WO2011064247A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
US20200362002A1 (en) * 2017-12-29 2020-11-19 Hoffmann-La Roche Inc. Process for providing pegylated protein composition
WO2019129876A1 (en) * 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition
WO2019129877A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition
KR20230060524A (ko) 2020-12-08 2023-05-04 통화 안레이트 바이오파마슈티컬 컴퍼니 리미티드 재조합 단백질의 정제 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022512A2 (en) * 2005-08-19 2007-02-22 Neose Technologies, Inc. Glycopegylated factor vii and factor viia
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040731A1 (en) * 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
NZ507557A (en) * 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
EP1500661A1 (en) 1998-06-01 2005-01-26 Genetech, Inc. Separation of protein monomers from aggregates by use of ion-exchange chromatography
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7470779B2 (en) * 2002-09-20 2008-12-30 Pfizer Inc. Process for decreasing aggregate levels of pegylated protein
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
MXPA06006023A (es) * 2003-12-03 2006-08-23 Neose Technologies Inc Factor ix glicopegilado.
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
DK2125866T3 (da) 2007-02-28 2013-07-29 Baxter Int Fremgangsmåde til rensning af rekombinant blodkoagulationsfaktor IX, som er beriget med sulfaterede og/eller phosphorylerede molekyler

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022512A2 (en) * 2005-08-19 2007-02-22 Neose Technologies, Inc. Glycopegylated factor vii and factor viia
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
赵彦鼎等: "自制填充介质对人血浆凝血因子Ⅸ的层析分离", 《中国生物制品学杂志》 *

Also Published As

Publication number Publication date
WO2011064247A1 (en) 2011-06-03
JP5827955B2 (ja) 2015-12-02
JP2013511566A (ja) 2013-04-04
US8697844B2 (en) 2014-04-15
EP2504349A1 (en) 2012-10-03
CN107383158A (zh) 2017-11-24
US20120244137A1 (en) 2012-09-27
EP2504349B1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
JP5827955B2 (ja) Ｐｅｇ化タンパク質の精製方法
CN102112608B (zh) 在不存在其辅因子的情况下具有凝血活性的因子ix变体及其治疗出血障碍的用途
US8383776B2 (en) Purification of factor XIII polypeptides from biological materials
BRPI0712008A2 (pt) derivados e análogos de fix prolongados
CN102316893A (zh) 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
BRPI0816837A2 (pt) antídotos para inibidores do fator xa e métodos para sua utilização
JP2011519833A (ja) 半減期が延長された第ｉｘ因子コンジュゲート
US20050181978A1 (en) Therapeutic use of factor XI
Geddes et al. A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IXVancouver
KR20060118486A (ko) 인자 ｘｉ의 치료적 사용
CN112423782B (zh) FX活化方法及其在FXa组合物制备中的用途
US10851364B2 (en) Method of controlling a polypeptide modification reaction
WO2011018515A1 (en) Method of purifying pegylated proteins
ES2792473T3 (es) Método para purificar proteínas PEGiladas
MXPA06005477A (en) Therapeutic use of factor xi

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120815

RJ01 Rejection of invention patent application after publication